2022 Journal Article ctDNA as a biomarker of progression in oesophageal adenocarcinomaBonazzi, V. F., Aoude, L. G., Brosda, S., Lonie, J. M., Patel, K., Bradford, J. J., Koufariotis, L. T., Wood, S., Smithers, B. Mark, Waddell, N. and Barbour, A. P. (2022). ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open, 7 (3) 100452, 100452. doi: 10.1016/j.esmoop.2022.100452 |
2021 Journal Article Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patientsAoude, Lauren G., Wong, Bernadette, Bonazzi, Vanessa F, Brosda, Sandra, Walters, Shaun B., Koufariotis, Lambros T., Naeini, Marjan M., Pearson, John V, Oey, Harald, Patel, Kalpana, Bradford, Julia J., Bloxham, Conor J, Atkinson, Victoria, Law, Phillip, Strutton, Geoffrey, Bayley, Gerard, Yang, Samuel, Smithers, B. Mark, Waddell, Nicola, Miles, Kenneth and Barbour, Andrew P. (2021). Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients. Molecular Cancer Research, 19 (6) molcanres.1038.2020, 950-956. doi: 10.1158/1541-7786.mcr-20-1038 |
2020 Journal Article Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patientsAoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3 |
2015 Journal Article A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinomaWadt, K. A. W., Aoude, L. G., Johansson, P., Solinas, A., Pritchard, A., Crainic, O., Andersen, M. T., Kiilgaard, J. F., Heegaard, S., Sunde, L., Federspiel, B., Madore, J., Thompson, J. F., Mccarthy, S. W., Goodwin, A., Tsao, H., Jonsson, G., Busam, K., Gupta, R., Trent, J. M., Gerdes, A. -M., Brown, K. M., Scolyer, R. A. and Hayward, N. K. (2015). A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clinical Genetics, 88 (3), 267-272. doi: 10.1111/cge.12501 |
2015 Journal Article POLE mutations in families predisposed to cutaneous melanomaAoude, Lauren G., Heitzer, Ellen, Johansson, Peter, Gartside, Michael, Wadt, Karin, Pritchard, Antonia L., Palmer, Jane M., Symmons, Judith, Gerdes, Anne-Marie, Montgomery, Grant W., Martin, Nicholas G., Tomlinson, Ian, Kearsey, Stephen and Hayward, Nicholas K. (2015). POLE mutations in families predisposed to cutaneous melanoma. Familial Cancer, 14 (4), 621-628. doi: 10.1007/s10689-015-9826-8 |
2014 Journal Article Assessment of PALB2 as a candidate melanoma susceptibility geneAoude, Lauren G., Xu, Mai, Zhao, Zhen Zhen, Kovacs, Michael, Palmer, Jane M., Johansson, Peter, Symmons, Judith, Trent, Jeffrey M., Martin, Nicholas G., Montgomery, Grant W., Brown, Kevin M. and Hayward, Nicholas K. (2014). Assessment of PALB2 as a candidate melanoma susceptibility gene. PLoS One, 9 (6) e100683, e100683.1-e100683.7. doi: 10.1371/journal.pone.0100683 |
2013 Journal Article A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancersAoude, Lauren G., Wadt, Karin, Bojesen, Anders, Cruger, Dorthe, Borg, Ake, Trent, Jeffrey M., Brown, Kevin M., Gerdes, Anne-Marie, Jonsson, Goran and Hayward, Nicholas K. (2013). A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PloS One, 8 (8) e72144, e72144. doi: 10.1371/journal.pone.0072144 |
2024 Journal Article Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapyBrosda, Sandra, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lonie, James M., Belle, Clemence J., Newell, Felicity, Koufariotis, Lambros T., Addala, Venkateswar, Naeini, Marjan M., Simes, John, Walpole, Euan T., Mai, Gang T., Watson, David I., Karapetis, Chris S., Gebski, Val, Barnes, Elizabeth H., Oostendorp, Martijn, Wilson, Kate, Ackland, Stephen P., Shannon, Jenny, Marx, Gavin, Burge, Matthew, Finch, Robert, Thomas, Janine, Varma, Suresh, Nott, Louise, Pearson, John V., Krause, Lutz ... AGITG DOCTOR Investigators (2024). Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy. Genome Medicine, 16 (1) 90, 90. doi: 10.1186/s13073-024-01362-z |
2024 Journal Article POT1 and multiple primary melanomas: the dermatological phenotypeMaas, Ellie J., DeBortoli, Emily, Nathan, Vaishnavi, Freeman, Ned P., Mothershaw, Adam, Smit, Darren J., Betz-Stablein, Brigid, Aoude, Lauren G., Stark, Mitchell S., Sturm, Richard A., Soyer, H. Peter and McInerney-Leo, Aideen M. (2024). POT1 and multiple primary melanomas: the dermatological phenotype. Journal of Medical Genetics, 61 (9) jmg-2023-109637, 1-4. doi: 10.1136/jmg-2023-109637 |
2024 Journal Article The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspectiveYee, Joshua, Rosendahl, Cliff and Aoude, Lauren G. (2024). The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective. Melanoma Research, 34 (2), 96-104. doi: 10.1097/cmr.0000000000000951 |
2023 Journal Article The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobankLonie, James M., Brosda, Sandra, Bonazzi, Vanessa F., Aoude, Lauren G., Patel, Kalpana, Brown, Ian, Sharma, Sowmya, Lampe, Guy, Addala, Venkateswar, Koufariotis, Lambros T., Wood, Scott, Waddell, Nicola, Dolcetti, Riccardo and Barbour, Andrew P. (2023). The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank. Frontiers in Immunology, 14 1220129, 1-15. doi: 10.3389/fimmu.2023.1220129 |
2023 Journal Article ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patientsAoude, Lauren G., Brosda, Sandra, Ng, Jessica, Lonie, James M., Belle, Clemence J., Patel, Kalpana, Koufariotis, Lambros T., Wood, Scott, Atkinson, Victoria, Smithers, B. Mark, Pearson, John V., Waddell, Nicola, Barbour, Andrew P. and Bonazzi, Vanessa F. (2023). ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients. Journal of Molecular Diagnostics, 25 (10), 771-781. doi: 10.1016/j.jmoldx.2023.06.014 |
2023 Journal Article GOLM1: expanding our understanding of melanoma susceptibilityMaas, Ellie J., Wallingford, Courtney K., DeBortoli, Emily, Smit, Darren J., Betz-Stablein, Brigid, Aoude, Lauren G., Stark, Mitchell S., Sturm, Richard A., Soyer, H. Peter and McInerney-Leo, Aideen M. (2023). GOLM1: expanding our understanding of melanoma susceptibility. Journal of Medical Genetics, 60 (9) jmg-2023-109348, 1-3. doi: 10.1136/jmg-2023-109348 |
2023 Journal Article C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsBonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.13993 |
2023 Journal Article Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapyM. Naeini, Marjan, Newell, Felicity, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lampe, Guy, Koufariotis, Lambros T., Lakis, Vanessa, Addala, Venkateswar, Kondrashova, Olga, Johnston, Rebecca L., Sharma, Sowmya, Brosda, Sandra, Holmes, Oliver, Leonard, Conrad, Wood, Scott, Xu, Qinying, Thomas, Janine, Walpole, Euan, Tao Mai, G., Ackland, Stephen P., Martin, Jarad, Burge, Matthew, Finch, Robert, Karapetis, Christos S., Shannon, Jenny, Nott, Louise, Bohmer, Robert, Wilson, Kate ... Waddell, Nicola (2023). Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nature Communications, 14 (1) 3155, 3155. doi: 10.1038/s41467-023-38891-x |
2023 Conference Publication Unusual suspects in hereditary melanoma: POT1, POLE and BAP1Maas, Ellie, Betz-Stablein, Brigid, Aoude, Lauren, Soyer, Hans Peter and McInerney-Leo, Aideen (2023). Unusual suspects in hereditary melanoma: POT1, POLE and BAP1. 55th European Society of Human Genetics (ESHG) Conference, Vienna, Austria, 11-14 June 2022. London, United Kingdom: Nature Publishing Group. |
2022 Journal Article Unusual suspects in hereditary melanoma: POT1, POLE, BAP1Maas, Ellie J., Betz-Stablein, Brigid, Aoude, Lauren G., Soyer, H. Peter and McInerney-Leo, Aideen M. (2022). Unusual suspects in hereditary melanoma: POT1, POLE, BAP1. Trends in Genetics, 38 (12), 1204-1207. doi: 10.1016/j.tig.2022.06.007 |
2022 Conference Publication Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinomaAoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357 |
2022 Journal Article Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panelsRamarao-Milne, P, Kondrashova, O, Patch, A-M, Nones, K, Koufariotis, L T, Newell, F, Addala, V, Lakis, V, Holmes, O, Leonard, C, Wood, S, Xu, Q, Mukhopadhyay, P, Naeini, M M, Steinfort, D, Williamson, J P, Bint, M, Pahoff, C, Nguyen, P T, Twaddell, S, Arnold, D, Grainge, C, Basirzadeh, F, Fielding, D, Dalley, A J, Chittoory, H, Simpson, P T, Aoude, L G, Bonazzi, V F ... Waddell, N (2022). Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. ESMO Open, 7 (4) 100540, 1-11. doi: 10.1016/j.esmoop.2022.100540 |
2022 Conference Publication Classification of esophageal adenocarcinoma into subgroups that are associated with patient survival using RNA-seq and immunohistochemistrySharma, Sowmya, Naeini, Marjan, Aoude, Lauren G., Bonazzi, Vanessa F., Gartside, Michael G., Loffler, Kelly A., Patel, Kalpana, Newell, Felicity, Lampe, Guy, Brosda, Sandra, Thomas, Janine, Smithers, Mark, Simes, John, Watson, David I., Pearson, John, Barbour, Andrew and Waddell, Nic (2022). Classification of esophageal adenocarcinoma into subgroups that are associated with patient survival using RNA-seq and immunohistochemistry. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |